相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Infectious Diseases
Shirley L. L. Kwok et al.
Summary: This study observed the antibody levels in 850 fully vaccinated individuals in Hong Kong's COVID-19 vaccination program using ELISA and surrogate virus neutralization test. The results showed that the antibody levels remained above the positive cut-off values within the first 6 months. However, the antibody levels in the CoronaVac-vaccinated group started to decline below the cut-off values after 4 months.
Article
Immunology
Mark A. Brockman et al.
Summary: Humoral responses to COVID-19 mRNA vaccines are significantly weaker in older adults, and decline over time. Age is a significant predictor of antibody concentration and virus neutralizing activity, even after adjusting for participant demographics.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Medicine, General & Internal
Lisa M. Dunkle et al.
Summary: The NVX-CoV2373 vaccine has shown to be safe and highly effective in preventing Covid-19, with a vaccine efficacy of 90.4% against reverse-transcriptase-polymerase-chain-reaction-confirmed cases and 100% efficacy against moderate-to-severe disease. The vaccine also demonstrated high efficacy against various variants of the virus.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Multidisciplinary Sciences
Peter B. Gilbert et al.
Summary: In the COVE phase 3 clinical trial, neutralizing and binding antibodies were measured in vaccine recipients to determine their correlation with COVID-19 risk and vaccine efficacy. The results showed that these immune markers were inversely associated with COVID-19 risk and directly associated with vaccine efficacy. Postvaccination neutralization titers of 10, 100, and 1000 correlated with estimated vaccine efficacies of 78%, 91%, and 96% respectively.
Article
Infectious Diseases
Deborah Cromer et al.
Summary: By analyzing data on in-vitro neutralization and clinical protection, the study found that neutralizing activity against the ancestral SARS-CoV-2 is highly correlated with neutralization of variants of concern, and can still predict the vaccine's protection against these variants. Simulation results suggest that booster vaccination for previously infected individuals can provide higher levels of protection compared to primary vaccination. Although the protection may decrease within the first year after vaccination, the current vaccines can still offer robust protection in the medium term.
Article
Immunology
Taisei Masuda et al.
Summary: This study evaluated the safety and immunogenicity of the NVX-CoV2373 vaccine in healthy Japanese participants. The results showed that two doses of NVX-CoV2373 given with a 21-day interval demonstrated acceptable safety and induced robust anti-SARS-CoV-2 immune responses in healthy Japanese adults.
Article
Multidisciplinary Sciences
Laura Perez-Alos et al.
Summary: This study examines the dynamics of immunological markers after the first dose of SARS-CoV-2 vaccination in a cohort of healthcare professionals in Denmark. The results suggest that natural infection leads to higher antibody responses, and the decline of IgG levels varies depending on factors such as age, sex, T-cell response, previous infection, and interval between vaccine doses.
NATURE COMMUNICATIONS
(2022)
Article
Infectious Diseases
Raches Ella et al.
Summary: The BBV152 vaccine demonstrated tolerable safety outcomes and enhanced immune responses in this clinical trial, leading to selection of both Algel-IMDG formulations for phase 2 immunogenicity trials. Further efficacy trials are warranted to validate the vaccine's effectiveness.
LANCET INFECTIOUS DISEASES
(2021)
Article
Medicine, General & Internal
Raches Ella et al.
Summary: The study reported the clinical efficacy of the BBV152 vaccine against COVID-19 infection in Indian adults. The vaccine demonstrated high efficacy in preventing laboratory-confirmed symptomatic COVID-19 and was well tolerated with no safety concerns raised in this interim analysis.
Article
Medicine, General & Internal
Ann R. Falsey et al.
Summary: The clinical trial in the United States, Chile, and Peru showed that the AZD1222 vaccine was both safe and effective in preventing symptomatic and severe Covid-19 cases, with an overall estimated efficacy of 74% and a higher efficacy of 83.5% in participants 65 years of age or older. The high vaccine efficacy was consistent across various demographic subgroups, and antibodies increased significantly after each dose.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Infectious Diseases
Raches Ella et al.
Summary: BBV152 vaccine, consisting of whole-virion inactivated SARS-CoV-2 with Algel and IMDG, showed high neutralizing antibody responses in phase 1 trial and better reactogenicity in phase 2 trial. The 6 mu g with Algel-IMDG formulation has been chosen for phase 3 efficacy trial.
LANCET INFECTIOUS DISEASES
(2021)
Article
Immunology
Pilar Vizcarra et al.
Summary: The study showed that pre-existing SARS-CoV-2-specific cellular immunity can affect the reactogenicity of the BNT162b2 mRNA COVID-19 vaccine, with different reactions observed in various groups after vaccination.
Article
Medicine, General & Internal
Neil Formica et al.
Summary: This study confirmed the high immunogenicity and good tolerability of the 2-dose regimen of 5-mu g NVX-CoV2373 in younger adults. Additionally, in older adults, the 2-dose regimen of 5 mu g was also well tolerated and showed sufficient immunogenicity to support its use in late-phase efficacy studies.
Article
Immunology
Alborz Rahmani et al.
Summary: Vaccinations are crucial in combatting the COVID-19 pandemic, with the BNT162b2 mRNA vaccine being widely used in Italy. A study on resident doctors in Genoa revealed common adverse reactions following the first and second doses, with some impacting daily activities for the young working age population.
Article
Medicine, General & Internal
Paul T. Heath et al.
Summary: The NVX-CoV2373 vaccine demonstrated an efficacy of 89.7% in a phase 3 trial with over 15,000 participants, with mild and transient reactogenicity. It showed high efficacy against the B.1.1.7 variant and a low incidence of adverse events.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Prasad S. Kulkarni et al.
Summary: The study demonstrated that the Indian-manufactured SII-ChAdOx1 nCoV-19 vaccine is comparable to the AZD1222 vaccine in terms of immunogenicity and safety, showing good immune response and acceptable safety profile. The study also revealed a low rate of SARS-CoV-2 infections post-vaccination, with no severe adverse events reported.
Article
Immunology
Lisa Mueller et al.
Summary: The study compared antibody responses to the BNT162b2 COVID-19 vaccine in young vaccinees below 60 and elderly vaccinees over 80. The elderly group had lower antibody titers and a lower frequency of neutralizing antibodies post-vaccination, indicating a potential need for closer monitoring or different vaccination strategies for this population.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Medicine, General & Internal
Yun Woo Lee et al.
Summary: This study found that the rate of adverse reactions in healthcare workers after receiving both doses of the BNT162b2 mRNA vaccine significantly increased after the second dose, especially muscle ache, fatigue, headache, chills, and fever. Females had a significantly higher frequency of adverse reactions after the second dose, while older age groups had lower rates of adverse reactions.
JOURNAL OF KOREAN MEDICAL SCIENCE
(2021)
Article
Medicine, General & Internal
Cheryl Keech et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
Letter
Public, Environmental & Occupational Health
Priyanka et al.
TRAVEL MEDICINE AND INFECTIOUS DISEASE
(2020)
